China Finalizes Landmark Dual-Track Drug Reimbursement Reform, Ushering New Era for Innovative Pharma Access
Monday, November 24, 2025
In November 2025, China’s National Healthcare Security Administration achieved a milestone in medical access reform by concluding negotiations for two pivotal policy initiatives: the latest round of the National Reimbursement Drug List (NRDL) and the inaugural Commercial Health Insurance Innovative Drug List (CHIIDL). This marks the first time that China’s health system has adopted a dual-track payment system—combining state-backed basic medical insurance with a market-driven commercial health coverage designed specifically to accelerate access to highly innovative, high-value drugs. These changes are set to formally transform China’s healthcare landscape starting January 1, 2026, and carry extensive implications for pharmaceutical executives, drug developers, investors, and regulatory strategists across Asia and globally.
The historic addition of the CHIIDL addresses a key market gap: therapies that are clinically transformative but historically excluded from public reimbursement due to high costs. Traditional NRDL inclusion requires adherence to stringent price caps—typically below RMB 500,000 at entry and below RMB 300,000 for success—which often precluded CAR-T therapies and advanced biologics from consideration. With the CHIIDL, multinational pharma and biotech innovators now have a new route to market. The list is purpose-built for agents with significant breakthrough value where commercial health insurance, not basic medical insurance, assumes the primary payer role. This market-oriented mechanism allows for flexible, individually-negotiated terms, expanding both access and coverage for advanced therapies without overburdening public budgets.
For B2B pharmaceutical stakeholders, the strategic implications are profound. Pharma manufacturers and licensors can now simultaneously apply for both NRDL and CHIIDL inclusion, leveraging a streamlined expert review, negotiation, and fast-track adoption process in hospitals. In 2025’s review round, 24 innovative products entered CHIIDL consideration, parallel to 127 NRDL candidates—potentially opening the door to therapies previously blocked by financial or administrative barriers. The reforms are expected to foster earlier revenue realization, scale acceleration, and improved local market access for companies bringing advanced drugs to China.
However, successful commercialization depends on actual hospital uptake and reimbursement workflow integration. The policy includes significant “three exemptions” for CHIIDL-listed drugs—removing them from basic insurance caps, procurement monitoring, and DRG-based payment rules. While dramatically lowering administrative obstacles, it does not guarantee immediate product flow into clinical settings. Accordingly, leading cities like Shanghai, Hangzhou, Shandong, and Xiamen have launched digital “one-stop settlement platforms,” enabling real-time insurance verification and reimbursement for commercial innovative drug lists. Shandong alone processed over 36 million cases and RMB 2.1 billion in direct CHIIDL-linked transactions by August 2025, highlighting scalable digital infrastructure as key to uptake.
Despite these advances, coverage sustainability and premium design remain challenges. Existing commercial health products—such as the popular “Hui Min Bao” municipal plans—cover only about 45% of non-NRDL drugs and are ill-equipped for ultra-expensive products without facing potential withdrawal spirals or unsustainable risk pools. Experts advocate for employer-based group health insurance and long-term medical insurance models, drawing on US group insurance’s 85% market share, as sustainable frameworks to absorb expensive innovative therapies while maintaining affordability and scale.
The global significance of this dual-track reform lies in its demonstration of a hybrid, multi-layered financing model—potentially a new blueprint for emerging pharmaceutical markets balancing innovation incentives with universal coverage. For global manufacturers, investors, and regional distributors, the imminent release and January 2026 launch of both the NRDL and CHIIDL signal a decisive policy shift. China’s reforms could set new regulatory and commercial standards for drug market access not only in Asia but in other emerging economies. Pharmaceutical leaders are advised to prioritize regulatory intelligence, adapt access strategies, and closely monitor the forthcoming public release of drug lists for 2026 to stay ahead of market dynamics shaped by this evolving landscape.
